Faroq Kamli

Faroq Kamli

Auto-generated profile, based on publicly available information

Faroq Kamli

Department of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan, 45142, Saudi Arabia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2026 in Current Medicinal Chemistry
Verified
Journal Article
Open access
GKGyas Khan
Gyas Khan
AHAli Hanbashi
Ali Hanbashi
WMWedad Mawkili
Wedad Mawkili
FKFaroq Kamli
Faroq Kamli
MAMd. Sajid Ali
Md. Sajid Ali
MHMd Sadique Hussain
Md Sadique Hussain
Cancer stem cells (CSCs) participate in cancer initiation, metastasis, and therapy tolerance, presenting a formidable challenge in cancer treatment. Antibody-drug conjugates (ADCs) have been established as a potential strategy for selectively targeting and eradicating CSCs, thereby overcoming resistance mechanisms and preventing tumor recurrence. ADCs integrate a monoclonal antibody specific to CSC surface markers, such as CD44, CD133, EpCAM, and ALDH1, with a potent cytotoxic payload linked by a stable chemical linker. Upon antigen binding, ADCs undergo receptor-mediated internalization, leading to intracellular payload release and CSC apoptosis. Recent advances in ADC technology have enhanced selectivity and efficacy while minimizing off-target toxicity. Preclinical studies demonstrate that CSC-targeted ADCs, including CD133- and CD44-directed therapies, effectively deplete CSC populations in glioblastoma, breast, colorectal, and lung cancers. EpCAM-targeted ADCs have also shown efficacy in epithelial tumors with potential synergy in combination immunotherapies. Moreover, emerging approaches, such as bispecific antibodies and optimized linker chemistry, further refine CSC-targeted ADCs for clinical applications. Despite these advancements, challenges remain, including CSC heterogeneity, immune evasion, and limitations in biomarker specificity. Addressing these hurdles requires continued innovation in ADC engineering, novel payloads, and combinatory strategies with immune checkpoint inhibitors or CAR-T cell therapies. While clinical evaluations are still in the early phases, preliminary trials underscore the potential of CSC-targeted ADCs in revolutionizing precision oncology. This review explores the mechanisms, recent developments, and prospects of CSC-targeted ADCs, highlighting their transformative potential in cancer immunotherapy.

22 July 2025 in Epigenomics
Verified
Journal Article
Closed access
MHMd Sadique Hussain
Md Sadique Hussain
YKYumna Khan
Yumna Khan
MMMudasir Maqbool
Mudasir Maqbool
GKGyas Khan
Gyas Khan
WMWedad Mawkili
Wedad Mawkili
Prawez AlamPrawez Alam
Prawez Alam
Prostate cancer (PCa) is one of the most common cancers in men, distinguished by a multifaceted pathogenesis that involves substantial epigenetic modifications. This article emphasizes the critical role of chromatin remodeling in PCa advancement. Chromatin remodeling, a key epigenetic mechanism, influences gene expression by modulating the chromatin structure through the action of specialized complexes such as SWI/SNF, ISWI, CHD, & INO80, thereby regulating genes vital to tumor progression. A comprehensive literature search was conducted using PubMed, Web of Science, and Scopus databases for studies published between 2000 and 2025, focusing on chromatin remodeling, epigenetic alterations, and therapeutic strategies in PCa. The review discusses the major epigenetic changes observed in PCa, including DNA and RNA methylation, histone modifications, and non-coding RNA (ncRNA)-mediated chromatin remodeling. The evolving epigenetic landscape shaped by these alterations offers insights into novel therapeutic opportunities. The clinical relevance of targeting chromatin remodeling complexes is explored, alongside existing therapies and potential future interventions. This review also addresses challenges in studying chromatin remodeling and highlights emerging technologies that could enhance understanding of PCa epigenetics. This comprehensive exploration underscores the promise of chromatin remodeling as both a biomarker and a therapeutic target in PCa management.

1 April 2026 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
ARAmita Joshi Rana
Amita Joshi Rana
MHMd Sadique Hussain
Md Sadique Hussain
AHAli Hanbashi
Ali Hanbashi
FKFaroq Kamli
Faroq Kamli
GKGyas Khan
Gyas Khan
GGGaurav Gupta
Gaurav Gupta
The use of CRISPR-Cas9 to engineer cancer cell lines has made it possible to precisely examine how cancer cells react to different drugs and therapies. Some of the key improvements are in the use of Mediator Complex Subunit 12 (MED12)-knockout cells to study cell resistance to BRAF inhibitors, CRISPR models of epithelial-mesenchymal transition for breast cancer, and pharmacogenomic analysis in various cancer cell lines. CRISPR is used in immunotherapy to help Chimeric Antigen Receptor T (CAR-T) cells function better by disrupting the immune checkpoints like Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-lymphocyte- associated protein 4 (CTLA-4) and to adapt T cells to react with various antigens. As a result of these innovations, it is now possible to track how cancers like non-small cell lung cancer (NSCLC) and ovarian cancer evolve, change their epigenetic features, and find strategies to reverse their resistance. Moving forward, integrating AI analytics, single-cell multi-omics, patient-derived organoids, and CRISPR mechanisms will help improve precision oncology and speed up effective treatment planning.

30 January 2025 in Saudi Journal of Health Research & Practice
Verified
Journal Article
Open access
AJAbdulmajeed Mohammed Jali
Abdulmajeed Mohammed Jali
MOHAMMAD FIROZ ALAMMOHAMMAD FIROZ ALAM
MOHAMMAD FIROZ ALAM
SSSulaiman Sayyar
Sulaiman Sayyar
FKFaroq Kamli
Faroq Kamli
AZAli Zarban
Ali Zarban
AHAli Hanbashi
Ali Hanbashi
Acetaminophen is widely used as an analgesic and antipyretic, but its potential for nephrotoxicity, particularly in overdose situations, remains a significant concern. Identifying agents that can mitigate this nephrotoxicity is crucial for kidney protection. Barbeya oleoides Schweinfurth (BOL), known for its antioxidant and anti-inflammatory properties, may offer protective effects against acetaminophen-induced kidney injury. This study investigates the nephroprotective potential of an ethanolic extract from BOL leaves against acetaminophen-induced nephrotoxicity. Five groups of rats (n = 6 per group) were treated orally for seven days: Group 1 received a placebo solution (vehicle), Group 2 received a single acetaminophen dose (2 g/kg) on day 5, Groups 3 and 4 received BOL at doses of 100 or 200 mg/kg, respectively, along with acetaminophen on day 5, and Group 5 received only BOL (200 mg/kg). Acetaminophen significantly increased the level of the kidney function biomarkers blood urea nitrogen (BUN), triglycerides (TG), uric acid (UA), and creatinine, indicating renal dysfunction. It also elevated pro-inflammatory cytokines, specifically tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), highlighting an inflammatory response. Furthermore, a notable reduction in antioxidant enzyme levels, namely glutathione (GSH), catalase (CAT), and superoxide dismutase (SOD), was observed, signifying oxidative stress and impaired antioxidant defense. Histopathological examination showed disruption of the glomerular basement membrane, confirming renal tissue damage. BOL co-treatment restored kidney function biomarkers and antioxidant levels, reduced cytokine levels, and preserved renal tissue structure suggesting improved oxidative balance. In conclusion, BOL leaves extract demonstrated significant nephroprotective effects against acetaminophen-induced nephrotoxicity by reducing oxidative stress and inflammation, highlighting its potential as an adjunct therapy to prevent acetaminophen-induced kidney injury.